高级检索
阮玉华, 徐校平, 童政, 周卫群, 邵守坤, 顾惠心, 徐志一. 肾综合征出血热Ⅰ型灭活疫苗预防接种成本效益和效果分析[J]. 中国公共卫生, 1999, 15(7): 603-605.
引用本文: 阮玉华, 徐校平, 童政, 周卫群, 邵守坤, 顾惠心, 徐志一. 肾综合征出血热Ⅰ型灭活疫苗预防接种成本效益和效果分析[J]. 中国公共卫生, 1999, 15(7): 603-605.
Ruan Yuhua, . Cost Benefit and Effectiveness Analysis of Type iv Inactivated Vaccine against Hemorrhagic Fever with Renal Syndrome[J]. Chinese Journal of Public Health, 1999, 15(7): 603-605.
Citation: Ruan Yuhua, . Cost Benefit and Effectiveness Analysis of Type iv Inactivated Vaccine against Hemorrhagic Fever with Renal Syndrome[J]. Chinese Journal of Public Health, 1999, 15(7): 603-605.

肾综合征出血热Ⅰ型灭活疫苗预防接种成本效益和效果分析

Cost Benefit and Effectiveness Analysis of Type iv Inactivated Vaccine against Hemorrhagic Fever with Renal Syndrome

  • 摘要: 对肾综合征出血热Ⅰ型灭活疫苗进行成本效益和效果分析,为肾综合征出血热免疫预防策略的制定提供依据。以建德市肾综合征出血热Ⅰ型灭活疫苗现场效果考核资料为基础,分5个不同年龄组队列,计算各组的效益费用比(BCR)和费用效果比(CER)。各年龄组BCR和CER均分别小于1和大于0。30~39岁年龄组CER值11080.82元最小,接近于人均国民生产总值(1.08万元),其他各组CER均较大,灵敏度分析显示疫苗费?保护率和保护期对CER和BCR影响大。高危人群20~29?30~39和40~49岁年龄组CER均小于人均国民生产总值。结论:预防接种肾综合征出血热灭活疫苗未获正效益;30~39岁年龄组,其次是40~49岁和20~29岁年龄组是首选接种人群;15~59岁高危人群均需接种疫苗,其中20~49岁是重点接种人群。

     

    Abstract: Cost benenfit and effectiveness analysis of type iv inactivated vaccine againsthemorrhagic fever with renal syndrome was conducted and it was guildline for strategy of immunizing-with type iv inactiveated vaccine against HFRS.Based on materials of epide-milogy efficacy of type iv inactivated vaccines against HFRS in Jiande county.Benefit-cost ratio (BCR) and Cosi-effective ratio (CER) were estimated for 5 cohorts of different age groups.BCR and CER of all age groups were under 1 and above respectively.CER of 30~39 age group (11080.82 yuan REM) was almost to the average pecapital GDP(10800 yuan) and CER of other age groups was larger.Sensitivity analysis showed that vaccine cost,protect rate and protect period of vaccine affected CER and BCR more.CER of 20~29,30~39 and 40~49 age groups with high risk were under GDP.It couldn’t obtain benefit of inactivatedvac-cines inoculated against HFRS;The first people immunlized with inactivated vaccine against HFRS was 30~39 age group and the next peoples were 40~49 age and 20~29 age group;Vaccine can be used to cover the population of high risk of age 15~59 years old,but the key population of vaccine gived was 20~49 age groups.

     

/

返回文章
返回